«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2022 02

Page:

256-260

Research Field:

Publishing date:

Info

Title:

Expression of RSK4 in clear cell renal cell carcinoma tissues and its clinical significance

Author(s):

MA Jing¹; 2; CHAI Jia¹; 2; WANG Kaijing¹; 2; LIU Yixiong¹; 2; XU Junpeng³; ZHANG Xiumin¹; 2

1.Department of Pathology,Air Force Military Medical University,Shaanxi Xi'an 710032,China;2.Department of Pathology,Xijing Hospital,Air Force Military Medical University,Shaanxi Xi'an 710032,China;3.The 31666 Troop of PLA,Gansu Wuwei 733000,China.

Keywords:

clear cell renal cell carcinoma; RSK4; proliferation; prognosis

PACS:

R737.11

DOI:

10.3969/j.issn.1672-4992.2022.02.016

Abstract:

Objective£ºTo investigate the expression of RSK4 protein in clear cell renal cell carcinoma (ccRCC),and to explore the level of expressions as well as the association with clinicopathologic features and clinical outcome.Methods:The expression of RSK4 in 48 ccRCC and 20 hydronephrosis samples were detected by immunohistochemistry and its relationship with clinicopathologic features as well as prognosis were analyzed by statistical methods.Results:In the 48 ccRCC samples,there were 36 (75%,36/48) positive for RSK4,while the positive rate in hydronephrosis samples were 5 (25%,5/20).Statistical analysis showed that the expression of RSK4 in ccRCC samples are higher than the hydronephrosis samples (P£¼0.05).Furthermore,the expression of RSK4 in ccRCC samples weren' t correlated with ages and genders (P£¾0.05),while WHO/ISUP nucleolar grade was associated with poor survival (P£¼0.05).Molecular studies showed that overexpression of RSK4 could enhance the proliferation abilities of ccRCC cell lines.Conclusion:The expression pattern and molecular mechanisms of RSK4 in ccRCCs indicate that it could be a potential independent prognostic factor and serve as a new potential therapeutic target for RCC patients,and its specific mechanism of action remains to be further studied.

References:

£Û1£Ý SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2012£ÛJ£Ý.CA Cancer J Clin,2012,62(1):10-29.
£Û2£Ý EDGE SB,COMPTON CC.The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM£ÛJ£Ý.Ann Surg Oncol,2010,17(6):1471-1474.
£Û3£Ý YNTEMA HG,VAN DEN HELM B,KISSING J,et al.A novel ribosomal S6-kinase (RSK4;RPS6KA6) is commonly deleted in patients with complex X-linked mental retardation£ÛJ£Ý.Genomics,1999,62(3):332-343.
£Û4£Ý DEWDNEY SB,RIMEL B,THAKER PH,et al.Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers£ÛJ£Ý.Clinical Cancer Research,2011,17(8):2120-2129.
£Û5£Ý ARECHAVALETA-VELASCO F,ZEFERINO-TOQUERO M,ESTRADA-MOSCOSO I,et al.Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines£ÛJ£Ý.Medical Oncology,2016,33(2):11.
£Û6£Ý CHEN L,XU T,JIA Q,et al.RSK4:a new prognostic factor in glioma£ÛJ£Ý.Pathol Res Pract,2020,216(8):153020.
£Û7£Ý THAKUR A,XU H,WANG Y,et al.The role of X-linked genes in breast cancer£ÛJ£Ý.Breast Cancer Res Treat,2005,93(2):135-143.
£Û8£Ý FAN L,LI P,YIN Z,et al.Ribosomal S6 protein kinase 4:a prognostic factor for renal cell carcinoma£ÛJ£Ý.British Journal of Cancer,2013,109(5):1137-1146.
£Û9£Ý SPECHT E,KAEMMERER D,S¦FNGER J,et al.Comparison of immunoreactive score,HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms£ÛJ£Ý.Histopathology,2015,67(3):368-377.
£Û10£Ý MOORE LE,HUNG R,KARAMI S,et al.Folate metabolism genes,vegetable intake and renal cancer risk in central Europe£ÛJ£Ý.Int J Cancer,2008,122(8):1710-1715.
£Û11£Ý CHEN W,HILL H,CHRISTIE A,et al.Targeting renal cell carcinoma with a HIF-2 antagonist£ÛJ£Ý.Nature,2016,539(7627):112-117.
£Û12£Ý HARTMAN KG,VITOLO MI,PIERCE AD,et al.Complex formation between S100B protein and the p90 ribosomal S6 kinase (RSK) in malignant melanoma is calcium-dependent and inhibits extracellular signal-regulated kinase (ERK)-mediated phosphorylation of RSK£ÛJ£Ý.Journal of Biological Chemistry,2014,289(18):12886-12895.
£Û13£Ý ZHOU Y,YAMADA N,TANAKA T,et al.Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2£ÛJ£Ý.Nature Communications,2015,6(1):7679.
£Û14£Ý TSAI HC,CHENG SP,HAN CK,et al.Resistin enhances angiogenesis in osteosarcoma via the MAPK signaling pathway£ÛJ£Ý.Aging (Albany NY),2019,11(21):9767-9777.
£Û15£Ý ROUX PP,BLENIS J.ERK and p38 MAPK-activated protein kinases:a family of protein kinases with diverse biological functions£ÛJ£Ý.Microbiol Mol Biol Rev,2004,68(2):320-344.
£Û16£Ý LOO V,SALGIA M,BERGEROT P,et al.First-line systemic therapy for metastatic clear-cell renal cell carcinoma:Critical appraisal of emerging options£ÛJ£Ý.Target Oncol,2019,14(6):639-645.
£Û17£Ý LI H,SUN T,LIU C,et al.Photobiomodulation (450 nm) alters the infection of via the ROS/MAPK/mTOR signaling pathway£ÛJ£Ý.Free Radic Biol Med,2020,152:838-853.
£Û18£Ý REDDY D,GHOSH P,KUMAVATH R.Strophanthidin attenuates MAPK,PI3K/AKT/mTOR,and Wnt/beta-Catenin signaling pathways in human cancers£ÛJ£Ý.Front Oncol,2019,9:1469.
£Û19£Ý LAND SC,TEE AR.Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif£ÛJ£Ý.J Biol Chem,2007,282(28):20534-20543.
£Û20£Ý MASOUD GN,LI W.HIF-1¦Á pathway:role,regulation and intervention for cancer therapy£ÛJ£Ý.Acta Pharm Sin B,2015,5(5):378-389.
£Û21£Ý MI C,MA J,WANG KS,et al.Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1¦Á via the mTOR/p70S6K/4E-BP1 and MAPK pathways£ÛJ£Ý.J Ethnopharmacol,2017,203:27-38.

Memo

Memo:

National Natural Science Foundation of China(No.81472402£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð(±àºÅ£º81472402£©

Common functions

Last Update: 1900-01-01